Novo Nordisk And Life Edit Therapeutics Announced A Research And Development Collaboration To Discover And Develop Gene Editing Therapies Against A Select Set Of Therapeutic Targets.Under The Agreement, Life Edit Will Receive An Upfront Cash Payment And Is Eligible To Receive Potential Development, Regulatory, And Commercial Milestones Of 335 Million Us Dollars For Each Of The First Two Development Programmes Under The Collaboration And Up To 250 Million Dollars For Each Of The Following Five Development Programmes Under The Collaboration. The Collaboration Between The Two Companies Allows For Development Of Up To Seven Programmes. Moreover, This Opportunity Will Co-Create Novel Treatments For Multiple Genetic Diseases Based On Life Edit
